2026.03
R&D Progress
BST001 Deuterated Glucose Tracer Submits Pre-IND Application
The company has submitted a pre-IND application to the NMPA, advancing clinical registration of the world's first deuterated glucose molecular tracer.
NEWS
Follow Biosotop's R&D, registration and partnership progress
Around stable-isotope drugs, MR metabolic imaging and the drug-device ecosystem, recording the company's key milestones from research breakthroughs to clinical translation.
Latest Updates
R&D registration and business cooperation advancing in parallel
Read more
2026
Business Cooperation
Advancing Sales and Clinical Collaboration with the World's Four Major MRI Vendors
Centered on 3T, 5T and 7T multi-nuclear MR systems, advancing the deployment of deuterium metabolic imaging across research and clinical scenarios.
2025
Partner Ecosystem
Strategic Cooperation Agreements Signed with GE and United Imaging
Partnering with equipment vendors to advance metabolic-MR equipment upgrades, tracer integration and clinical translation.
2023
Research Achievement
Research on 5-Deuterated Glucose Featured on the Cover of NMR in Biomedicine
The company's deuterated glucose product matches international benchmarks in performance and has obtained a granted Chinese invention patent.
Media Kit
Core information for understanding Biosotop
Company positioning, product pipeline, clinical value and partner ecosystem — the four most important categories for media coverage and industry communication.
Company Profile
Product Pipeline
Technology Platform
Partner Ecosystem